Format

Send to

Choose Destination
Br J Cancer. 2017 May 9;116(10):1312-1317. doi: 10.1038/bjc.2017.91. Epub 2017 Apr 11.

Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer.

Author information

1
Laboratory of Translational Immunology, University Medical Center, Utrecht 3584 CX, The Netherlands.
2
Department of Internal Medicine, St Antonius Hospital, Nieuwegein 3435 CM, The Netherlands.
3
Department of Pulmonology, Jeroen Bosch Hospital, Den Bosch 5223 GZ, The Netherlands.
4
Department of Medical Oncology, Erasmus Medical Center, Rotterdam 3075 EA, The Netherlands.
5
Department of Internal Medicine, Meander Medical Center, Amersfoort 3813 TZ, The Netherlands.
6
Department of Medical Oncology, University Medical Center Utrecht, Utrecht 3584 CX, The Netherlands.
7
Department of Pharmacy, Radboud UMC, Nijmegen 6525 GA, The Netherlands.

Abstract

BACKGROUND:

Cabazitaxel is approved for treatment of castration-resistant metastatic prostate cancer. The current dosing strategy of cabazitaxel is based on body surface area (BSA). Body surface area is known as a poor predictor for total systemic exposure to drugs, since it does not take into account variability in activity of metabolising enzymes, necessary for clearance of drugs. As exposure to cabazitaxel is related to treatment response, it is essential to develop a better individualised dosing strategy.

METHODS:

Ten patients with metastatic castration-resistant prostate cancer, who received cabazitaxel dosed on BSA as a part of routine palliative care, were enrolled in this study. Midazolam was administered as phenotyping probe for cytochrome P450 isoenzyme 3A (CYP3A). The relationship between midazolam and cabazitaxel clearance was investigated using non-linear mixed effects modelling.

RESULTS:

The clearance of Midazolam highly correlated with cabazitaxel clearance (R=0.74). Midazolam clearance significantly (P<0.004) explained the majority (∼60%) of the inter-individual variability in cabazitaxel clearance in the studied population.

CONCLUSIONS:

Metabolic phenotyping of CYP3A using midazolam is a promising strategy to individualise cabazitaxel dosing. Before clinical application, a randomised study is warranted.

PMID:
28399110
PMCID:
PMC5482735
DOI:
10.1038/bjc.2017.91
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center